Clinical Trial Update: Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating perioperative sintilimab plus a bevacizumab biosimilar and TACE-HAIC for hepatocellular carcinoma with PVTT is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING